Publications by authors named "Emmalie Schoepke"

Physical exercise induces physiologic adaptations and is effective at reducing the risk of premature death from all causes. Pharmacological exercise mimetics may be effective in the treatment of a range of diseases including obesity and metabolic syndrome. Previously, we described the development of SLU-PP-332, an agonist for the estrogen-related receptor (ERR), and nuclear receptors that activates an acute aerobic exercise program.

View Article and Find Full Text PDF

Estrogen-related receptors (ERR) are an orphan nuclear receptor sub-family that play a critical role in regulating gene transcription for several physiological processes including mitochondrial function, cellular energy utilization and homeostasis. They have also been implicated to play a role in several pathological conditions. Herein, we report the identification, synthesis, structure-activity relationships and pharmacological evaluation of a new chemical series of potent pan-ERR agonists.

View Article and Find Full Text PDF

Liver X Receptors (LXRs) are members of the nuclear receptor family, and they play significant role in lipid and cholesterol metabolism. Moreover, they are key regulators of several inflammatory pathways. Pharmacological modulation of LXRs holds great potential in treatment of metabolic diseases, neurodegenerative diseases, and cancer.

View Article and Find Full Text PDF

The estrogen related receptors (ERRs) are a subgroup of nuclear receptors that play a role in regulation of cellular metabolism. Prostate cancer (PCa) cells display altered metabolic signatures, such as the Warburg effect, and the ERRs have been implicated in driving this phenotype. Despite the lack of a known endogenous ligand, synthetic ligands that target the ERRs have been discovered.

View Article and Find Full Text PDF
Article Synopsis
  • Natural product molecules, especially tetracyclic terpenoids, are crucial for developing new pharmaceutical drugs, with over 100 FDA-approved options.
  • Despite their success, challenges in obtaining these compounds limit their broader medicinal use.
  • The study introduces a new asymmetric method to create C19 and C20 tetracyclic terpenoids, showing promising results as selective agonists of the estrogen receptor beta and effective against glioblastoma cell lines.
View Article and Find Full Text PDF